Robert S. Rosenson, MD, on Secondary Prevention of ASCVD

In this podcast, Robert S. Rosenson, MD, discusses recent research about secondary prevention of atherosclerotic cardiovascular disease (ASCVD) and the implications of the research for clinical practice.

Robert S. Rosenson, MD, is a professor of medicine at Mount Sinai Heart at the Icahn School of Medicine at Mount Sinai in New York, New York. He is also the section editor of Lipid and Metabolic Disorders at the Journal of the American College of Cardiology and section editor of Lipid Disorders for Up to Date Medicine.

Additional Resources:

• Colantonio LD, Shannon ED, Orroth KK, et al. Ischemic event rates in very-high-risk adults. J Am Coll Cardiol. 2019;74(20):2496-2507. https://doi.org/10.1016/j.jacc.2019.09.025.
• Bittner V, Colantonio LD, Dai Y, et al. Association of region and hospital and patient characteristics with use of high-intensity statins after myocardial infarction among Medicare beneficiaries. JAMA Cardiol. 2019;4(9):865-872. https://doi.org/10.1001/jamacardio.2019.2481.
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;73(24):e285-e350. https://doi.org/10.1016/j.jacc.2018.11.003. 
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01764633. Published February 15, 2018. Updated August 21, 2019. Accessed February 7, 2020. ClinicalTrials.gov Identifier: NCT01764633.
• ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01663402. Published March 18, 2019. Updated March 18, 2019. Accessed February 7, 2020. ClinicalTrials.gov Identifier: NCT01663402.
• Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019;41(1):111-188. https://doi.org/10.1093/eurheartj/ehz455. 
• IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00202878. Published September 30, 2015. Updated September 21, 2018. Accessed February 7, 2020. ClinicalTrials.gov Identifier: NCT00202878. 
• Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al; AKCEA-APO(a)-L_RX Study Investigators. New Engl J Med. 2020;382(3):244-255. https://doi.org/10.1056/nejmoa1905239.